Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
1 December 2016
Published paper using MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL.
Seminar at Glasgow Caledonian University: Local Health Care Expenditure Plans and Their Opportunity Costs
11 January 2016
OHE’s Sarah Karlsberg Schaffer presented at the Glasgow Health Economics Seminar Series the results of a paper on the value of the cost-effectiveness threshold in Scotland.
Uncertainty and Risk in HTA Decision Making
1 November 2016
The quality of decision-making in key public sector bodies dealing with resource allocation is a major determinant of their efficiency. One of the most difficult and contentious areas of decision-making is the way that uncertainty is dealt with.
How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
8 January 2016
This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting, Tokyo. The panel session was entitled “How…
“New Age” Decision Making in HTA: Is It Applicable in Asia?
1 August 2016
This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting in Tokyo. The panel session was entitled…
A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications
1 May 2016
NICE’s decisions exert an influence on the allocation of fixed NHS budgets, but decisions for different types of health interventions (for example drugs and devices) are…
OHE at the Health Economists’ Study Group (HESG) Meeting, Manchester 2016
4 January 2016
A summary of OHE’s activity at the 2016 winter HESG meeting, Manchester, 6-8th January.
Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
4 January 2016
This report details the views of a selection of experts in the fields of health and welfare economics on the cost-effectiveness threshold used by the National…
Cost-per-QALY in the US and Britain
28 December 2015
Professor Weinstein compares the use of cost-per-QALY approaches in the UK and the US. Britain has got it closer to right, but may go a little…